Mediawire
New Delhi [India], April 30: Pulmonary fibrosis (PF) is a progressive interstitial lung disease (ILD) characterized by excessive fibrotic tissue deposition in the pulmonary parenchyma. The term “pulmonary” refers to the lungs, while “fibrosis” denotes pathological scarring. The disease disrupts normal alveolar architecture, leading to impaired gas exchange, reduced lung compliance, and progressive respiratory insufficiency.
PF encompasses over 200 ILDs, with idiopathic pulmonary fibrosis (IPF) being the most common and severe form. Histopathologically, PF features chronic inflammation, fibroblast proliferation, and excessive extracellular matrix deposition, predominantly collagen. Unlike inflammatory ILDs, IPF follows an irreversible fibrotic course, leading to a steady decline in lung function.
Global and Regional Prevalence of Pulmonary Fibrosis
Pulmonary fibrosis is a growing global health concern with varying epidemiological trends. In Western populations, IPF prevalence ranges from 2 to 29 cases per 100,000 individuals, with incidence increasing due to aging populations and improved diagnostic capabilities. The disease predominantly affects males aged 50 to 70 years.
In India, PF remains underrecognized, especially in primary care settings. While tertiary centres frequently diagnose PF, awareness among general practitioners is inadequate. Studies suggest that IPF accounts for 29-48% of diffuse parenchymal lung disease (DPLD) cases in Indian hospitals. Factors such as air pollution, occupational exposures, biomass fuel inhalation, and smoking suggest that PF cases may be significantly underestimated.
Risk Factors and Etiology of Pulmonary Fibrosis
PF etiology is multifactorial, involving both intrinsic and extrinsic contributors:
* Environmental and Occupational Exposure: Chronic inhalation of inorganic and organic particulates, such as silica, asbestos, and coal dust, can induce lung fibrosis. Hypersensitivity pneumonitis from organic dusts like bird droppings and Mold spores can also lead to fibrosis.
* Iatrogenic Causes: Radiation therapy, cytotoxic drugs (e.g., bleomycin, methotrexate, amiodarone), and certain antibiotics are associated with lung fibrosis.
* Tobacco Use: Smoking accelerates disease progression and worsens clinical outcomes.
* Autoimmune Diseases: Systemic disorders such as rheumatoid arthritis, systemic
* sclerosis, and Sjogren’s syndrome are strongly associated with pulmonary fibrosis.
* Genetic Susceptibility: Mutations in genes encoding surfactant proteins (SFTPC, SFTPA2), telomerase components (TERT, TERC), and mucin-producing proteins (MUC5B) have been linked to familial pulmonary fibrosis.
* Gastroesophageal Reflux Disease (GERD): Chronic micro aspiration of gastric contents contributes to persistent alveolar injury and fibrotic remodelling.
Clinical Presentation of Pulmonary Fibrosis Early recognition of PF is crucial for timely intervention. Common clinical manifestations include:
* Progressive exertional dyspnea
* Persistent dry, non-productive cough
* Fatigue and generalized myalgia
* Unexplained weight loss and anorexia
* Digital clubbing due to chronic hypoxia
* Bibasilar inspiratory “Velcro crackles” on auscultation
Untreated PF can lead to complications such as pulmonary hypertension, right ventricular dysfunction (cor pulmonale), acute exacerbations, and an increased risk of lung malignancies.
Diagnostic Approach to Pulmonary Fibrosis
PF is often misdiagnosed as chronic obstructive pulmonary disease (COPD), asthma, or pneumonia. A multimodal diagnostic approach is essential:
1. Clinical Assessment: Detailed history, symptomatology, and occupational/environmental exposure evaluation.
2. Pulmonary Function Tests (PFTs):
Restrictive ventilatory defect (reduced forced vital capacity [FVC] with preserved FEV1/FVC ratio).
Decreased diffusion capacity of the lungs for carbon monoxide (DLCO).
3. Imaging Studies:
High-resolution computed tomography (HRCT): Identifies reticular opacities, honeycombing, and traction bronchiectasis, characteristic of PF.
4. Laboratory Tests:
Autoimmune serology (ANA, RF, anti-CCP) for connective tissue disease- associated PF.
5. Lung Biopsy (in select cases): Surgical lung biopsy or transbronchial lung cryobiopsy may be required for definitive histopathological diagnosis.
Management and Treatment Strategies
Although fibrotic lung tissue is irreversible, several therapeutic options can slow disease progression and alleviate symptoms:
* Antifibrotic Agents:
* Pirfenidone: Reduces fibroblast proliferation and collagen deposition.
* Nintedanib: A tyrosine kinase inhibitor that targets profibrotic pathways (VEGFR, FGFR, and PDGFR).
* Immunomodulators (for non-IPF PF): Corticosteroids, azathioprine, or mycophenolate mofetil in autoimmune-related cases.
* Oxygen Therapy: Supplemental oxygen improves exercise tolerance and reduces hypoxic complications.
* Pulmonary Rehabilitation: Supervised exercise programs and breathing techniques enhance functional capacity.
* Lung Transplantation: The only curative option for advanced-stage PF, with patient selection based on pulmonary function impairment, oxygen dependence, and overall health status.
Role of Support Systems in Pulmonary Fibrosis Care
Comprehensive PF management extends beyond pharmacological interventions. Multidisciplinary care teams comprising pulmonologists, physiotherapists, dietitians, and psychologists play a pivotal role. Patient advocacy groups, caregiver networks, and telemedicine programs enhance disease awareness and provide essential psychosocial support.
Future Perspectives and Conclusion
Historically, IPF prognosis was poor, with a median survival of 3-5 years post-diagnosis. However, emerging therapies and early intervention have improved life expectancy. Novel antifibrotic agents, regenerative medicine approaches (stem cell therapy), and gene-targeted interventions hold promise for transforming PF management.
Increasing disease awareness, improving diagnostic capabilities, and expanding treatment accessibility are critical to combating pulmonary fibrosis. A multifaceted approach combining pharmacotherapy, lifestyle modifications, and robust support systems will be instrumental in improving patient outcomes and quality of life.
Dr. A.R. Gayathri Devi
M.D., FCCP, FRCP, European Diploma in Respiratory Medicine,
Senior Consultant Pulmonologist,
Apollo Hospitals, Chennai
Quote:
Patients with pulmonary fibrosis often present with unexplained breathlessness and chronic dry cough. Early referral to a pulmonologist can prevent delays in diagnosis and initiation of treatment.
Dr Partha Pratim Bose
MD, DTCD, DNB, FISDA, FBPI, MBA
Senior consultant & Faculty
Pulmonologist, National Heart Institute, New Delhi
Founder SAANS foundation, India
Quote:
Fibrosis is a progressive condition that can affect various organs, leading to scarring and impaired function. Early diagnosis and management are key to slowing its progression. Patients should be aware of symptoms like persistent fatigue, shortness of breath, or unexplained pain. A healthy lifestyle, regular check-ups, and timely medical intervention can make a significant difference.
Dr Shubhranshu
MBBS, MD
Consultant Pulmonologist
Jeevan Rekha Hospital, Jaipur
Quote:
Pulmonary fibrosis is a progressive lung disease that leads to scarring, making breathing increasingly difficult. Symptoms like chronic cough, fatigue, and shortness of breath are often mistaken for aging or other conditions, delaying diagnosis. While there is no cure, early detection can slow progression and improve quality of life. Raising awareness is crucial–if you or a loved one experience these symptoms, seek medical advice promptly. Timely intervention saves lives.
Dr Amit Kumar Mandal
Director
Pulmonology, Sleep and Critical Care, Fortis Hospital, Mohali.
Quote:
While pulmonary fibrosis has no known cure, certain precautions can help reduce the risk. Avoid exposure to harmful pollutants, quit smoking, and prioritize lung health through regular exercise and medical check-ups. Early detection is key–if you experience persistent breathlessness or chronic cough, seek medical advice promptly. Protect your lungs today to breathe easier tomorrow. Awareness and prevention are the first steps toward a healthier future.
Dr Viswesvaran Balasubramanian
MD, DM (Pulmonary Medicine and Critical care – Gold medallist)
Fellowship in Interventional Pulmonology (Malaysia) & Sleep Medicine
Senior Consultant- Interventional Pulmonology, ECMO & Lung Transplantation team
Yashoda Hospitals, Somajiguda, Hyderabad
Fibrosis is a silent threat that can damage vital organs over time. Early detection and proactive care are key to managing its impact. Stay informed, prioritize regular check-ups, and adopt a healthy lifestyle to safeguard your well-being. Awareness today can prevent complications tomorrow.
Disclaimer: This is a Sun Pharma initiative aimed at raising awareness about pulmonary fibrosis.
(ADVERTORIAL DISCLAIMER: The above press release has been provided by Mediawire. ANI will not be responsible in any way for the content of the same)
Disclaimer: This story is auto-generated from a syndicated feed of ANI; only the image & headline may have been reworked by News Services Division of World News Network Inc Ltd and Palghar News and Pune News and World News
HINDI, MARATHI, GUJARATI, TAMIL, TELUGU, BENGALI, KANNADA, ORIYA, PUNJABI, URDU, MALAYALAM
For more details and packages
